Table 1.
Baseline characteristics
| Characteristic | Healthy controls (n = 13) | DMD patients(n = 17) | P value |
|---|---|---|---|
| Age (years) | 15.7 (11.1–20.7) | 13.4 (12.5–16.7) | 0.536 |
| Calculated height (m) | 1.73 (1.47–1.75) | 1.54 (1.47–1.66) | 0.053 |
| BMI (kg/m2) | 19.5 (16.4–22.3) | 27.5 (23.4–31.6) | 0.001 |
| Right‐handed | 12 (92.3%) | 13 (76.5%) | |
| Prednisone intermittent | NA | 8 (47.1%) | |
| Deflazacort intermittent | NA | 8 (47.1%) | |
| Deflazacort daily | NA | 1 (5.9%) | |
| Steroids on‐day at baseline | NA | 7 (41.1%) | |
| Steroids off‐day at baseline | NA | 10 (58.8%) | |
| Age at start steroid use (years) | NA | 5.7 (4.6–8.0) | |
| Age at loss of ambulation (years) | NA | 11.6 (10.1–12.8) range 8.6–18.9 | |
| Time since loss of ambulation (years) | NA | 2.6 (1.4–4.0) |
Values are median (first‐third quartiles) or number of patients (%). Statistical significance was set at P < 0.05.
BMI, body mass index; DMD, Duchenne muscular dystrophy.